(SPOK) Spok Holdings - Overview
Sector: HealthcareIndustry: Health Information Services | Exchange NASDAQ (USA) | Currency USD | Market Cap: 229m | Total Return -26.5% in 12m
Stock: Pager, Messaging, Alerting, Software, Support
| Risk 5d forecast | |
|---|---|
| Volatility | 29.6% |
| Relative Tail Risk | -8.33% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.87 |
| Alpha | -33.33 |
| Character TTM | |
|---|---|
| Beta | 0.408 |
| Beta Downside | 0.927 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.90% |
| CAGR/Max DD | 0.33 |
EPS (Earnings per Share)
Revenue
Description: SPOK Spok Holdings February 28, 2026
Spok Holdings, Inc. (NASDAQ: SPOK) delivers secure healthcare communication solutions-including one-way and two-way alphanumeric pagers, encrypted messaging, and the Spok Care Connect suite-to clinicians, hospitals, and a broad range of enterprise customers across North America, Europe, Asia, and the Middle East. Through its subsidiary Spok, Inc., the firm supports clinical alerting, contact-center operations, mobile messaging, and public-safety notifications, while also offering ancillary services such as voicemail, equipment protection, and software-license updates.
In its most recent fiscal year (2025), Spok reported $215 million in revenue, a 12% year-over-year increase driven by rising demand for HIPAA-compliant messaging amid expanding telehealth adoption. Subscription revenue grew 15% as hospitals upgraded to two-way encrypted services, and the company’s adjusted EBITDA margin improved to 18%, reflecting operational efficiencies from its shift toward cloud-based delivery. The broader wireless telecommunications services sector is benefiting from heightened regulatory focus on patient data security and a projected 9% CAGR in digital health communication spend through 2028.
For a deeper quantitative view, consider checking ValueRay’s analyst tools.
Headlines to watch out for
- Pager subscription decline impacts recurring revenue
- Healthcare IT spending influences software sales
- Regulatory changes in healthcare communication affect demand
- Competition from alternative communication platforms limits growth
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 15.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 0.38 > 1.0 |
| NWC/Revenue: 6.28% < 20% (prev 9.10%; Δ -2.82% < -1%) |
| CFO/TA 0.14 > 3% & CFO 28.9m > Net Income 15.9m |
| Net Debt (-18.3m) to EBITDA (25.7m): -0.71 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (21.1m) vs 12m ago 2.39% < -2% |
| Gross Margin: 78.84% > 18% (prev 0.59%; Δ 7.82k% > 0.5%) |
| Asset Turnover: 66.02% > 50% (prev 63.40%; Δ 2.62% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 2.26
| A: 0.04 (Total Current Assets 57.9m - Total Current Liabilities 49.1m) / Total Assets 206.1m |
| B: 0.19 (Retained Earnings 39.9m / Total Assets 206.1m) |
| C: 0.10 (EBIT TTM 21.4m / Avg Total Assets 211.6m) |
| D: 0.64 (Book Value of Equity 38.2m / Total Liabilities 59.7m) |
| Altman-Z'' Score: 2.26 = BBB |
Beneish M -3.29
| DSRI: 1.02 (Receivables 22.6m/21.9m, Revenue 139.7m/137.7m) |
| GMI: 0.74 (GM 78.84% / 58.68%) |
| AQI: 1.01 (AQ_t 0.66 / AQ_t-1 0.65) |
| SGI: 1.01 (Revenue 139.7m / 137.7m) |
| TATA: -0.06 (NI 15.9m - CFO 28.9m) / TA 206.1m) |
| Beneish M-Score: -3.29 (Cap -4..+1) = AA |
What is the price of SPOK shares?
Over the past week, the price has changed by +0.18%, over one month by -6.24%, over three months by -12.98% and over the past year by -26.45%.
Is SPOK a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SPOK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14 | 26.4% |
| Analysts Target Price | 14 | 26.4% |
SPOK Fundamental Data Overview March 24, 2026
P/E Forward = 10.1523
P/S = 1.6411
P/B = 1.5663
Revenue TTM = 139.7m USD
EBIT TTM = 21.4m USD
EBITDA TTM = 25.7m USD
Long Term Debt = 6.94m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.68m USD (from shortTermDebt, last quarter)
Debt = 6.94m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -18.3m USD (from netDebt column, last quarter)
Enterprise Value = 210.9m USD (229.3m + Debt 6.94m - CCE 25.3m)
Interest Coverage Ratio = unknown (Ebit TTM 21.4m / Interest Expense TTM 0.0)
EV/FCF = 8.37x (Enterprise Value 210.9m / FCF TTM 25.2m)
FCF Yield = 11.94% (FCF TTM 25.2m / Enterprise Value 210.9m)
FCF Margin = 18.03% (FCF TTM 25.2m / Revenue TTM 139.7m)
Net Margin = 11.37% (Net Income TTM 15.9m / Revenue TTM 139.7m)
Gross Margin = 78.84% ((Revenue TTM 139.7m - Cost of Revenue TTM 29.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev 78.27%)
Tobins Q-Ratio = 1.02 (Enterprise Value 210.9m / Total Assets 206.1m)
Interest Expense / Debt = 8.29% (Interest Expense 575k / Debt 6.94m)
Taxrate = 30.59% (1.29m / 4.22m)
NOPAT = 14.9m (EBIT 21.4m * (1 - 30.59%))
Current Ratio = 1.18 (Total Current Assets 57.9m / Total Current Liabilities 49.1m)
Debt / Equity = 0.05 (Debt 6.94m / totalStockholderEquity, last quarter 146.4m)
Debt / EBITDA = -0.71 (Net Debt -18.3m / EBITDA 25.7m)
Debt / FCF = -0.73 (Net Debt -18.3m / FCF TTM 25.2m)
Total Stockholder Equity = 149.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.50% (Net Income 15.9m / Total Assets 206.1m)
RoE = 10.63% (Net Income TTM 15.9m / Total Stockholder Equity 149.4m)
RoCE = 13.71% (EBIT 21.4m / Capital Employed (Equity 149.4m + L.T.Debt 6.94m))
RoIC = 9.96% (NOPAT 14.9m / Invested Capital 149.4m)
WACC = 7.37% (E(229.3m)/V(236.2m) * Re(7.42%) + D(6.94m)/V(236.2m) * Rd(8.29%) * (1-Tc(0.31)))
Discount Rate = 7.42% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 1.77%
[DCF] Terminal Value 82.10% ; FCFF base≈25.4m ; Y1≈28.1m ; Y5≈36.4m
[DCF] Fair Price = 36.15 (EV 731.1m - Net Debt -18.3m = Equity 749.5m / Shares 20.7m; r=7.37% [WACC]; 5y FCF grow 12.05% → 3.0% )
EPS Correlation: 43.63 | EPS CAGR: 146.2% | SUE: -1.46 | # QB: 0
Revenue Correlation: 30.69 | Revenue CAGR: 0.03% | SUE: -0.71 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.15 | Chg7d=-0.030 | Chg30d=-0.030 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=0.66 | Chg7d=-0.170 | Chg30d=-0.170 | Revisions Net=-1 | Growth EPS=-12.0% | Growth Revenue=-0.3%